Thermo Fisher Scientific Inc (TMO): Price and Financial Metrics
Thermo Fisher Scientific Inc (TMO)
Today's Latest Price: $441.63 USD
Updated Sep 30 2:40pm
Add TMO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
TMO Stock Summary
- With a market capitalization of $171,820,299,996, Thermo Fisher Scientific Inc has a greater market value than 99.15% of US stocks.
- TMO's went public 33.1 years ago, making it older than 91.59% of listed US stocks we're tracking.
- Price to trailing twelve month operating cash flow for TMO is currently 32.59, higher than 88.75% of US stocks with positive operating cash flow.
- Stocks that are quantitatively similar to TMO, based on their financial statements, market capitalization, and price volatility, are DHR, NVO, PEP, MDT, and NKE.
- Visit TMO's SEC page to see the company's official filings. To visit the company's web site, go to www.thermofisher.com.
TMO Stock Price Chart Technical Analysis Charts
TMO Price/Volume Stats
| Current price | $441.63 | 52-week high | $444.80 |
| Prev. close | $434.34 | 52-week low | $250.21 |
| Day low | $435.07 | Volume | 683,387 |
| Day high | $444.80 | Avg. volume | 1,691,827 |
| 50-day MA | $420.88 | Dividend yield | 0.2% |
| 200-day MA | $353.38 | Market Cap | 174.70B |
Thermo Fisher Scientific Inc (TMO) Company Bio
Thermo Fisher Scientific provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company was founded in 1956 and is based in Waltham, Massachusetts.
TMO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $441.63 | $164.89 | -62% |
We started the process of determining a valid price forecast for Thermo Fisher Scientific Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Thermo Fisher Scientific Inc ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Thermo Fisher Scientific Inc, consider:
- The stock's equity weight, or the proportion of capital from equity relative to debt, is 89. Its equity weight surpasses that of 60.52% of free cash flow generating stocks in the Healthcare sector.
- The business' balance sheet reveals debt to be 11% of the company's capital (with equity being the remaining amount). Approximately merely 24.65% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -63% |
| 1% | -62% |
| 2% | -62% |
| 3% | -62% |
| 4% | -61% |
| 5% | -61% |
Want more companies with a valuation profile/forecast similar to that of Thermo Fisher Scientific Inc? See GMED, HOLX, CAH, ENTA, and MDT.
Loading social stream, please wait...